JP2014527404A5 - - Google Patents

Download PDF

Info

Publication number
JP2014527404A5
JP2014527404A5 JP2014519553A JP2014519553A JP2014527404A5 JP 2014527404 A5 JP2014527404 A5 JP 2014527404A5 JP 2014519553 A JP2014519553 A JP 2014519553A JP 2014519553 A JP2014519553 A JP 2014519553A JP 2014527404 A5 JP2014527404 A5 JP 2014527404A5
Authority
JP
Japan
Prior art keywords
seq
vector
residue
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014519553A
Other languages
English (en)
Japanese (ja)
Other versions
JP6189293B2 (ja
JP2014527404A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/063640 external-priority patent/WO2013007772A1/en
Publication of JP2014527404A publication Critical patent/JP2014527404A/ja
Publication of JP2014527404A5 publication Critical patent/JP2014527404A5/ja
Application granted granted Critical
Publication of JP6189293B2 publication Critical patent/JP6189293B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014519553A 2011-07-12 2012-07-12 Hbvポリメラーゼ変異体 Expired - Fee Related JP6189293B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP11305909 2011-07-12
EP11305909.1 2011-07-12
EP12305450 2012-04-18
EP12305450.4 2012-04-18
PCT/EP2012/063640 WO2013007772A1 (en) 2011-07-12 2012-07-12 Hbv polymerase mutants

Publications (3)

Publication Number Publication Date
JP2014527404A JP2014527404A (ja) 2014-10-16
JP2014527404A5 true JP2014527404A5 (OSRAM) 2015-08-27
JP6189293B2 JP6189293B2 (ja) 2017-08-30

Family

ID=46506427

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014519553A Expired - Fee Related JP6189293B2 (ja) 2011-07-12 2012-07-12 Hbvポリメラーゼ変異体

Country Status (17)

Country Link
US (3) US9512412B2 (OSRAM)
EP (1) EP2732034B1 (OSRAM)
JP (1) JP6189293B2 (OSRAM)
KR (1) KR102061357B1 (OSRAM)
CN (1) CN103998604B (OSRAM)
AU (1) AU2012282506C1 (OSRAM)
BR (1) BR112014000627B1 (OSRAM)
CA (1) CA2841890C (OSRAM)
DK (1) DK2732034T3 (OSRAM)
ES (1) ES2632497T3 (OSRAM)
HU (1) HUE033789T2 (OSRAM)
IL (1) IL230402B (OSRAM)
MX (1) MX346835B (OSRAM)
PE (2) PE20141210A1 (OSRAM)
RU (1) RU2625021C2 (OSRAM)
TW (2) TWI623618B (OSRAM)
WO (1) WO2013007772A1 (OSRAM)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI623618B (zh) * 2011-07-12 2018-05-11 傳斯堅公司 Hbv聚合酶突變體
TWI690322B (zh) 2012-10-02 2020-04-11 法商傳斯堅公司 含病毒的調配物及其使用
JP2015128397A (ja) * 2014-01-08 2015-07-16 国立大学法人広島大学 亜リン酸デヒドロゲナーゼ遺伝子、および、当該遺伝子を用いた出芽酵母の選択的培養方法
WO2016020538A1 (en) * 2014-08-08 2016-02-11 Transgene Sa Hbv vaccine and antibody combination therapy to treat hbv infections
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
JP6566368B2 (ja) * 2015-04-16 2019-08-28 国立研究開発法人産業技術総合研究所 B型肝炎ウイルス分泌阻害剤
KR20180038465A (ko) 2015-08-07 2018-04-16 애로우헤드 파마슈티컬스 인코포레이티드 B형 간염 바이러스 감염에 대한 rnai 치료법
JP7250520B2 (ja) 2016-04-13 2023-04-03 ヤンセン ファーマシューティカルズ,インコーポレーテッド 組換えアルテリウイルスレプリコン系およびその使用
EP3452081A1 (en) 2016-05-04 2019-03-13 Transgene SA Combination therapy with cpg tlr9 ligand
JOP20170161A1 (ar) 2016-08-04 2019-01-30 Arrowhead Pharmaceuticals Inc عوامل RNAi للعدوى بفيروس التهاب الكبد ب
US20190328869A1 (en) 2016-10-10 2019-10-31 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
AU2017347725B2 (en) 2016-10-17 2024-01-04 Janssen Pharmaceuticals, Inc. Recombinant virus replicon systems and uses thereof
EP4242298A2 (en) * 2016-12-02 2023-09-13 Taiga Biotechnologies, Inc. Nanoparticle formulations
EP3548625B1 (en) 2016-12-05 2024-06-26 Janssen Pharmaceuticals, Inc. Compositions and methods for enhancing gene expression
GB201705765D0 (en) * 2017-04-10 2017-05-24 Univ Oxford Innovation Ltd HBV vaccine
JP7406377B2 (ja) 2017-05-15 2023-12-27 ヤンセン ファッシンズ アンド プリベンション ベーフェー 安定なウイルス含有組成物
US11306292B2 (en) 2017-05-15 2022-04-19 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
JOP20200153A1 (ar) * 2017-12-19 2022-10-30 Janssen Sciences Ireland Unlimited Co لقاحات التهاب الكبد الفيروسي b (hbv) واستخداماته
EA202091517A1 (ru) 2017-12-19 2020-11-03 Янссен Сайенсиз Айрлэнд Анлимитед Компани Способы и устройство для доставки вакцин против вируса гепатита b (hbv)
EA202091513A1 (ru) 2017-12-19 2020-09-09 Янссен Сайенсиз Айрлэнд Анлимитед Компани Вакцины против вируса гепатита b (hbv) и их применение
US11020476B2 (en) 2017-12-19 2021-06-01 Janssen Sciences Ireland Unlimited Company Methods and compositions for inducing an immune response against Hepatitis B Virus (HBV)
SG11202005709QA (en) * 2017-12-19 2020-07-29 Janssen Sciences Ireland Unlimited Co Methods and apparatus for the delivery of hepatitis b virus (hbv) vaccines
JP7494117B2 (ja) 2018-01-19 2024-06-03 ヤンセン ファーマシューティカルズ,インコーポレーテッド 組換えレプリコン系を使用する免疫応答の誘導および増強
AU2019231652B2 (en) * 2018-03-06 2025-05-22 Precigen, Inc. Hepatitis B vaccines and uses of the same
MX2020009262A (es) 2018-03-07 2021-01-08 Transgene Vectores de parapoxvirus.
AU2019359204B2 (en) 2018-10-08 2024-12-05 Janssen Pharmaceuticals, Inc. Alphavirus-based replicons for administration of biotherapeutics
AU2020272664A1 (en) 2019-04-08 2021-11-04 Taiga Biotechnologies, Inc. Compositions and methods for the cry opreservation of immune cells
AU2020274117A1 (en) 2019-05-14 2021-12-02 Taiga Biotechnologies, Inc. Compositions and methods for treating T cell exhaustion
US20220233684A1 (en) * 2019-06-18 2022-07-28 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and pd-l1 inhibitors
CA3141238A1 (en) * 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Hepatitis b virus (hbv) vaccines and uses thereof
WO2020255007A1 (en) * 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and hbv-targeting rnai
WO2020255011A1 (en) * 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 or anti-pd-l1 antibody
US20220305107A1 (en) * 2019-06-18 2022-09-29 Janssen Sciences Ireland Unlimited Company COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND HBV-TARGETING RNAi
WO2020255055A1 (en) * 2019-06-20 2020-12-24 Janssen Sciences Ireland Unlimited Company Self-replicating rna molecules for hepatitis b virus (hbv) vaccines and uses thereof
WO2020255063A1 (en) * 2019-06-20 2020-12-24 Janssen Sciences Ireland Unlimited Company Carbohydrate nanocarrier delivery of hepatitis b virus (hbv) vaccines
EP4458975A3 (en) * 2019-09-30 2025-02-12 Gilead Sciences, Inc. Hbv vaccines and methods treating hbv
CN111548395A (zh) * 2020-05-25 2020-08-18 中国农业科学院兰州兽医研究所 一种口蹄疫病毒二价多表位重组病毒样颗粒及其应用
KR20220117627A (ko) * 2021-02-17 2022-08-24 주식회사 녹십자 백신 조성물과의 병용을 위한 hbv 특이적 항체를 포함하는 b형 간염 치료용 조성물
CN115851656A (zh) * 2021-09-24 2023-03-28 中国科学院生物物理研究所 一种乙肝病毒聚合酶的制备方法
CN116333170A (zh) * 2023-03-28 2023-06-27 陇东学院 一种用于免疫治疗胃癌的重组病毒样纳米颗粒及其应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2650838A1 (fr) 1989-08-09 1991-02-15 Transgene Sa Vecteurs d'expression du facteur ix dans une cellule eucaryote superieure, procede de preparation de facteur ix par des animaux transgeniques et facteur ix obtenu
EP0534615B1 (en) 1991-08-26 2001-01-03 Epimmune Inc. HLA-restricted hepatitis B virus CTL epitopes
DE69434954T2 (de) 1993-02-26 2007-12-20 The Scripps Research Institute, La Jolla Peptide zum Induzieren einer Antwort der zytotoxischen T-Lymphozyten gerichtet gegen das Hepatitis-B-Virus
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
ATE227118T1 (de) * 1993-08-02 2002-11-15 Scripps Research Inst Peptide zum induzieren einer antwort der zytotoxischen t-lymphozythen gerichetetgegen das hepatitis b-virus
IL112820A0 (en) 1994-03-07 1995-05-26 Merck & Co Inc Coordinate in vivo gene expression
US5837520A (en) 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
EP1445322B2 (en) 1995-06-15 2012-06-06 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
IL127692A0 (en) 1996-07-01 1999-10-28 Rhone Poulenc Rorer Sa Method for producing recombinant adenovirus
AU732703B2 (en) 1996-11-20 2001-04-26 Crucell Holland B.V. An improved method for the production and purification of adenoviral vectors
CA2274876A1 (en) 1996-12-13 1998-06-18 Schering Corporation Method for purifying viruses
EP0988053A1 (en) 1997-06-11 2000-03-29 Aquila Biopharmaceuticals, Inc. Purified saponins as oral adjuvants
FR2766091A1 (fr) 1997-07-18 1999-01-22 Transgene Sa Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
JP3864610B2 (ja) 1998-05-21 2007-01-10 旭硝子株式会社 水分散型撥水撥油剤組成物およびその製造方法
US7462354B2 (en) * 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
PL373675A1 (en) * 2001-02-05 2005-09-05 Stressgen Biotechnologies Corporation Hepatitis b virus treatment
ES2322043T3 (es) 2001-06-22 2009-06-16 The Wistar Institute Of Anatomy And Biology Procedimientos de indusccion de una respuesta citotoxica inmune y composiciones de adenovirus de simio recombinante utiles en los mismos.
KR100987360B1 (ko) 2001-11-21 2010-10-12 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 원숭이 아데노바이러스 핵산과 아미노산 서열, 이를함유하는 벡터 및 사용방법
FR2836924B1 (fr) 2002-03-08 2005-01-14 Vivalis Lignees de cellules aviaires utiles pour la production de substances d'interet
GB0328753D0 (en) 2003-12-11 2004-01-14 Royal Veterinary College The Hepatitis B vaccines
ES2871907T3 (es) 2004-01-23 2021-11-02 Msd Italia Srl Portadores de vacuna de adenovirus de chimpancé
CN100339488C (zh) * 2004-12-07 2007-09-26 中山大学达安基因股份有限公司 乙型肝炎病毒基因组耐药突变检测方法
CN1313483C (zh) * 2005-12-12 2007-05-02 浙江大学 鸭乙型肝炎病毒多聚酶蛋白ymdd功能区的抑制肽及应用
KR101141333B1 (ko) 2006-06-20 2012-05-23 트랜스진 에스.에이. 재조합 바이러스 백신
CN101573449B (zh) 2006-08-14 2013-09-18 浦项工大产学协力团 用于治疗慢性乙型肝炎的dna疫苗及其制备方法
KR20080086687A (ko) 2007-03-23 2008-09-26 주식회사 파나진 라미부딘 내성 b형 간염바이러스 검출을 위한 ρνα프로브, 키트 및 방법
TW200844230A (en) 2007-05-15 2008-11-16 Transgene Sa Signaling peptides
US8357531B2 (en) 2007-07-03 2013-01-22 Transgene S.A. Immortalized avian cell lines
CN101688182A (zh) 2007-07-03 2010-03-31 特兰斯吉恩股份有限公司 永生化禽细胞系
EP2220217A2 (en) 2007-11-28 2010-08-25 The Trustees of the University of Pennsylvania Simian subfamily c adenoviruses sadv-40, -31, and-34 and uses thereof
CN101883858B (zh) 2007-11-28 2015-07-22 宾夕法尼亚大学托管会 猿猴亚家族E腺病毒SAdV-39、-25.2、-26、-30、-37和-38及其应用
CA2706257C (en) 2007-11-28 2017-06-06 The Trustees Of The University Of Pennsylvania Simian subfamily b adenovirus sadv-28, -27, -29, -32, -33 and -35 and uses thereof
CN102016011B (zh) 2008-03-04 2013-12-11 宾夕法尼亚大学托管会 猿猴腺病毒sadv-36、-42.1、-42.2和-44及其应用
MX2011007980A (es) 2009-02-02 2011-08-17 Okairos Ag Secuencias de acido nucleico y aminoacido de adenovirus de simio, vectores que contienen los mismos y usos de las mismas.
KR20120026526A (ko) 2009-05-12 2012-03-19 트랜스진 에스.에이. 불멸화 조류 세포주 및 그의 용도
WO2011001565A1 (ja) 2009-07-01 2011-01-06 シャープ株式会社 液晶表示素子及び液晶表示装置
NZ598000A (en) * 2009-08-07 2013-10-25 Transgene Sa Composition for treating hbv infection
TWI623618B (zh) * 2011-07-12 2018-05-11 傳斯堅公司 Hbv聚合酶突變體

Similar Documents

Publication Publication Date Title
JP2014527404A5 (OSRAM)
US10662414B2 (en) Methods for treating or preventing HBV infection or HBV related diseases
JP2013501038A5 (OSRAM)
CN103442732B (zh) 编码乙型肝炎病毒核心蛋白的核酸分子和包含其的疫苗
JP7317017B2 (ja) B型肝炎ウイルス(hbv)ワクチンおよびその使用
RU2012107671A (ru) Композиция для лечения инфекции вирусом гепатита в
CN111533812B (zh) 针对sars-cov-2病毒的dna疫苗及其用途
JP2021506300A (ja) B型肝炎ウイルス(hbv)に対する免疫応答を誘導するための方法および組成物
CN101717433A (zh) 一种多肽免疫原及其制备方法和应用
CN115335075A (zh) 治疗和预防乙型肝炎和丁型肝炎的组合物和方法
HK1192456B (en) Nucleic acid molecule encoding hepatitis b virus core protein and vaccine comprising the same
HK1192456A (en) Nucleic acid molecule encoding hepatitis b virus core protein and vaccine comprising the same